7.6 C
New York
Sunday, April 2, 2023

Momentum Is Strong For Vivos Therapeutics Inc. (NASDAQ: VVOS)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Vivos Therapeutics Inc. (VVOS) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.003, or 0.80%, to $0.376. The Vivos Therapeutics Inc. has recorded 8,083 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Vivos Therapeutics to Participate in Fireside Chat at the 35th Annual ROTH Conference.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


Stocks Info

Vivos Therapeutics Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Medical Devices industry. At the end of the last regular session, the stock closed at $0.37 and fluctuated between $0.4100 as its day high and $0.3700 as its day low. The current market capitalization of Vivos Therapeutics Inc. is $8.37M. A total of 0.56 million shares were traded on the day, compared to an average of 2.91M shares.

Insider Activity

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, VVOS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 0 SELLs from insiders. Insiders purchased 0 shares during that period but sold 0.

In the most recent transaction, Huntsman Ronald Kirk bought 20,000 shares of VVOS for 0.50 per share on Dec 23. After the transaction, the Chief Executive Officer now owns 47,500 company shares. In a previous transaction on Jun 01, Huntsman Ronald Kirk bought 4,000 shares at 1.83 per share. VVOS shares that Chief Executive Officer owns now total 27,500.

Among the insiders who bought shares, Huntsman Ronald Kirk acquired of 8,000 shares on May 31 at a per-share price of $2.03. This resulted in the Chief Executive Officer holding 23,500 shares of VVOS after the transaction.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for VVOS in the last 3 months, the mean price target is $2.38 with high estimates of $2.75 and low estimates of $2.00. In terms of 52-week highs and lows, VVOS has a high of $3.34 and a low of $0.34.

As of this writing, VVOS has an earnings estimate of $0 per share for the current quarter. EPS was calculated based on a consensus of 0 estimates, with a high estimate of $0 per share and a lower estimate of $0.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 2 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VVOS is Buy with a score of 5.00. A total of 2 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles